Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications
Safety and Tolerability Results from the PILLAR Study: A Phase IV, Double-Blind, Randomized, Placebo-Controlled Study of Mirabegron in Patients ≥ 65 years with Overactive Bladder-Wet.
Journal: Drugs & aging
Published: July 30, 2020
Antimuscarinic Discontinuation in Patients with Overactive Bladder in Nursing Homes: A Retrospective Study of Medicare Beneficiaries.
Journal: Advances in therapy
Published: April 22, 2020
Fall/Fracture-Related Healthcare Costs and Their Association with Cumulative Anticholinergic Burden in People with Overactive Bladder.
Journal: PharmacoEconomics - open
Published: April 16, 2020
Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS).
Journal: The Journal of urology
Published: January 03, 2020
Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR).
Journal: BMC geriatrics
Published: October 08, 2019
Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study.
Journal: BMJ open
Published: May 08, 2019
Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR).
Journal: European urology
Published: March 07, 2019
Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE).
Journal: Advances in therapy
Published: February 19, 2019
Cardiovascular safety of mirabegron: analysis of an integrated clinical trial database of patients with overactive bladder syndrome.
Journal: Journal of the American Society of Hypertension : JASH
Published: June 11, 2018
Impact of Fluid Choice in Systemic Inflammatory Response Syndrome Patients on Hospital Cost Savings.
Impact of Fluid Choice in Systemic Inflammatory Response Syndrome Patients on Hospital Cost Savings.
Journal: PharmacoEconomics - open
Published: April 07, 2018
Last Updated: 09/26/2026